Literature DB >> 11431443

TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes.

G Tezel1, L Y Li, R V Patil, M B Wax.   

Abstract

PURPOSE: To determine the expression and localization of tumor necrosis factor (TNF)-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes.
METHODS: Using immunohistochemistry and in situ hybridization, retinal expression and localization of TNF-alpha and TNF-alpha receptor-1 were studied in retina sections from 20 eyes of donors with glaucoma, and 20 eyes of age-matched normal donors.
RESULTS: According to immunohistochemistry, the intensity of the immunostaining and the number of labeled cells for TNF-alpha or its receptor were greater in retina sections of glaucomatous eyes than in control eyes of age-matched normal donors. In situ hybridization showed that mRNA signals for TNF-alpha or TNF-alpha receptor-1 were similarly more intense in glaucomatous eyes than in age-matched control eyes. Both protein and mRNA of TNF-alpha or TNF-alpha receptor-1 were predominantly localized to the inner retinal layers. Double-immunofluorescence labeling demonstrated that retinal immunostaining for TNF-alpha was predominantly positive in the glial cells, whereas immunostaining for TNF-alpha receptor-1 was mainly positive in the retinal ganglion cells.
CONCLUSIONS: Upregulation of TNF-alpha and its receptor-1 in glaucomatous retina suggest that TNF-alpha-mediated cell death is involved in the neurodegeneration process of glaucoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11431443

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  148 in total

1.  Preservation of retina ganglion cell function by morphine in a chronic ocular-hypertensive rat model.

Authors:  Shahid Husain; Yasir Abdul; Craig E Crosson
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-06-28       Impact factor: 4.799

2.  Glaucomatous tissue stress and the regulation of immune response through glial Toll-like receptor signaling.

Authors:  Cheng Luo; Xiangjun Yang; Angela D Kain; David W Powell; Markus H Kuehn; Gülgün Tezel
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-10       Impact factor: 4.799

3.  Peripheral visual field loss following treatment with etanercept.

Authors:  L J Clifford; J D Rossiter
Journal:  Br J Ophthalmol       Date:  2004-06       Impact factor: 4.638

4.  Opioid receptor activation: suppression of ischemia/reperfusion-induced production of TNF-α in the retina.

Authors:  Shahid Husain; Gregory I Liou; Craig E Crosson
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-04-20       Impact factor: 4.799

5.  Curcumin attenuates staurosporine-mediated death of retinal ganglion cells.

Authors:  Balabharathi Burugula; Bhagyalaxmi S Ganesh; Shravan K Chintala
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-16       Impact factor: 4.799

6.  Mechanisms of immune system activation in glaucoma: oxidative stress-stimulated antigen presentation by the retina and optic nerve head glia.

Authors:  Gülgün Tezel; Xiangjun Yang; Cheng Luo; Yong Peng; Sheher L Sun; Deming Sun
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-02       Impact factor: 4.799

Review 7.  Neuroprotection in glaucoma: drug-based approaches.

Authors:  William Cheung; Li Guo; M Francesca Cordeiro
Journal:  Optom Vis Sci       Date:  2008-06       Impact factor: 1.973

8.  The cell and molecular biology of glaucoma: mechanisms of retinal ganglion cell death.

Authors:  Robert W Nickells
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-05-04       Impact factor: 4.799

9.  Minocycline upregulates pro-survival genes and downregulates pro-apoptotic genes in experimental glaucoma.

Authors:  Hani Levkovitch-Verbin; Yael Waserzoog; Shelly Vander; Daria Makarovsky; Ilia Piven
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-02-25       Impact factor: 3.117

10.  Alzheimer's peptide and serine proteinase inhibitors in glaucoma and exfoliation syndrome.

Authors:  Sabina Janciauskiene; Torsten Krakau
Journal:  Doc Ophthalmol       Date:  2003-05       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.